+34 620 10 75 37info@nanbiosis.com

Nanbiosis

You are here : Home / Archive for "CIBER-BBN"

U1. Protein Production Platform Unit (PPP)

U1. Protein Production Platform (PPP)

U1. PPP logo IBB UAB

Order request
U1 PPP-Insect cells-Baculovirus as cell factoriesU1 PPP-Insect cells-Baculovirus as cell factories
U1 PPP-7L Bioreactor for protein productionU1 PPP-7L Bioreactor for protein production
U1 PPP–AKTA Purifier equipment for protein purificationU1 PPP–AKTA Purifier equipment for protein purification
U1 teamU1 team

Description

The PPP Unit is at the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona (IBB-UAB). It counts with the necessary facilities for the design, production, and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, led by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer a “tailored” service for the design, production, and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic, X-ray crystallography, and Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, another with all the necessary equipment for molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit has implemented the ISO9001 certification for standard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Brochure Unit 1 – PPP

Services

–

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % THE OF OPENNESS EACH SERVICE

U1. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017		 Coordinator

Other projects

Ref Title Funding Organism Unit Role
PI15/00272 Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer. Instituto de Salud Carlos III Participant
BIO2013-41019-P ENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDS MINECO Participant
2014SGR-132 Basic and Applied Microbiology AGAUR Participant
BIO2016-76063-R DEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERES MINECO Working package
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant
Marato 416/C/2030TV32013-132031 Genotoxic nanoparticles targeting colorectal cancer stem cells Marato TV3 Participant

Publications


2016

  • Corchero J.L. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies are produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

22 Apr

NANBIOSIS joins pioneering research on the permeability of epithelia for new Drug Delivery

NANBIOSIS Unit 1 supports study on c-CPE protein to modulate epithelial permeability, enabling safer, targeted drug delivery. Barcelona, april 2025. Researchers from the Institute of Biotechnology and Biomedicine (IBB) at the Universitat Autònoma de Barcelona (UAB) and other institutions have published a new study in Molecular Pharmaceutics demonstrating the dual behavior of a fragment of a bacterial toxin in modulating epithelial permeability. Thus providing with a key factor for improving drug delivery through epithelial barriers. The study, titled “Trans-Mediated, Cis-Inhibited Paradoxical Activity of Clostridium perfringens Enterotoxin (c-CPE) in Modulating Epithelial Permeability” (DOI: 10.1021/acs.molpharmaceut.4c01205), explores how the c-CPE domain of Clostridium[...]

15 Apr

NANBIOSIS contributes to innovative protein granules for new biomedical applications

Researchers from NANBIOSIS co-author a new study showcasing an innovative approach to protein-based biomaterials for drug delivery and regenerative medicine. Barcelona, april 2025. A recent publication in the International Journal of Biological Macromolecules highlights the cutting-edge work of scientists from Unit 1 (Protein Production Platform, PPP) and Unit 18 (Nanotoxicology Unit) of NANBIOSIS, under the leadership of Prof. Antonio Villaverde and Prof. Ramón Mangues, respectively. The study, entitled “Surpassing protein specificity in biomimetics of bacterial amyloids” (DOI: 10.1016/j.ijbiomac.2025.139635), explores the development of artificial protein granules with promising applications in biomedicine. A Novel Approach to Biomimetic Materials The research introduces a[...]

31 Mar

Breakthrough Nanotherapy for Colorectal Cancer: Innovative Research Involving NANBIOSIS

Breakthrough nanotherapy targets MSS colorectal cancer, inducing pyroptosis and immune activation. NANBIOSIS Units 1 and Unit 18 played a key role. Barcelona, march 2024. For this World Colorectal Cancer Day, researchers from Dr. Mangues’ group (CB06/01/1031), in which NANBIOSIS Unit 18 is integrated, have published just last month a groundbreaking study on a novel targeted nanotherapy for colorectal cancer. Conducted in collaboration with three CIBER research groups across two thematic areas (BBN and ER), this research highlights the potential of CXCR4-targeted nanotoxic therapy to combat microsatellite stable (MSS) colorectal cancer, a subtype known for its resistance to immune checkpoint inhibitors[...]

10 Dec

NANBIOSIS Unit invited to PEGS, the Protein & Antibody Engineering Summit

NANBIOSIS’s Protein Production Platform showcased innovations in protein engineering at PEGS Europe 2024, featuring talks, posters, and session moderation. Barcelona, november 2024. Last month, the NBT group and Unit 1 of NANBIOSIS (Protein Production Platform, PPP), from CIBER-BBN and IBB-UAB, was invited once again to participate in the prestigious PEGS Europe conference. PEGS Europe, a prestigous conference This year, the 16th PEGS Europe conference was held in Barcelona from November 5th to 7th. PEGS, or the Protein & Antibody Engineering Summit, is organized by the Cambridge Healthtech Institute (CHI) and is renowned for its focus on protein engineering and its[...]

18 Nov

The Protein Production Platform (PPP) at the UAB Innovation Fair

The PPP advances antimicrobial peptide research, forging partnerships to combat antibiotic resistance and prevent medical device-related infections. Barcelona, october 2024. During Antibiotic Awareness Week, we spotlight the Protein Production Platform (PPP) at NANBIOSIS Unit 1 for its pivotal role in combating antimicrobial resistance. At the recent UAB Innovation Fair, the PPP showcased its cutting-edge technologies and established collaborations with experts in bacterial biofilms and nanomaterials. Together, they aim to develop innovative antimicrobial peptides as alternatives to traditional antibiotics, targeting nosocomial infections linked to medical devices. These efforts underscore the critical importance of advancing research and partnerships to address one of[...]

10 Oct

Knowdlege growth: A chart-guide for cloning, production, purification, and characterization of recombinant proteins from prokaryotic systems

The Nanobiotechnology Group and NANBIOSIS PPP have created a poster-guide for recombinant protein cloning, production, and purification in prokaryotic systems. Barcelona, october 2024. The Nanobiotechnology Group, led by Prof. Villaverde, in collaboration with the NANBIOSIS Unit 1, Protein Production Platform (PPP), directed by Dr. Ferrer-Miralles, has created an in-depth guide in the form of a poster that compiles key strategies for cloning, production, purification, and characterization of recombinant proteins expressed in prokaryotic systems. Drawing from their vast experience in the field, they have meticulously outlined techniques and best practices to address common challenges and optimize every stage of the process.[...]

09 Oct

Harnessing Nanotechnology in protein research: Insights from Dr. Neus Ferrer on new ways of fighting antimicrobial resistance

Dr. Neus Ferrer explores nanotechnology in protein research to combat antimicrobial resistance, focusing on innovative solutions using lysins and other recombinant proteins. Barcelona, October 2024. In celebration of Nanotechnology Day, we take a closer look at the cutting-edge work of Dr. Neus Ferrer, director of the Unit 1, Protein Production Platform (PPP), at NANBIOSIS. Specializing in recombinant protein synthesis, Dr. Ferrer’s research tackles critical challenges in healthcare, particularly antimicrobial resistance, often referred to as the “new pandemic”. Through advanced nanotechnology approaches, her team in develops innovative solutions that could revolutionize treatment options in biomedicine and beyond. The interview begins… Interviewer:[...]

04 Apr

Protein-only Materials offer a new hope in colorectal cancer treatment

Breakthrough colorectal cancer treatment unveiled by NANBIOSIS Units promises enhanced precision & efficacy in targeted cancer therapies. March 2024, UAB/Institut de Recerca Sant Pau/CIBER-BBN (Barcelona) As we leave World Colorectal Cancer Day 2024 behind, marked on March 31st, there have been significant highlights in cancer treatment, a field in which targeted therapies are playing a crucial role. In this context, researchers from the Nanobiotechnology team, at the Institut de Biotecnologia i de Biomedicina from Universitat Autònoma de Barcelona, led by Prof. Antonio Villaverde, in collaboration with the Oncogenesis and Antitumor Drugs team led by Prof. Ramón Mangues at Institut d[...]

U1-Protein Production Platform - PPP
• Read More

U2. Custom Antibody Service Unit (CAbS)

U2 CAbS-hybridoma clone

U2. Custom Antibody Service (CAbS)

  • Scientific Director: Prof. Pilar Marco pilar.marco@cid.csic.es
  • Scientific Coordinator: Dr. Nuria Pascual npdqob@cid.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC

IQAC CSIC

Order request
U2 CAbS-Monoclonal antibody developmentU2 CAbS-Monoclonal antibody development
U2 CAbS-Hapten synthesisU2 CAbS-Hapten synthesis
U2 CAbS-Antibody purificationU2 CAbS-Antibody purification

Description

The facility is located in the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC; Barcelona). It is equipped with a laboratory for the development and production of monoclonal antibodies. The laboratory is fully equipped for obtaining, selecting and storing monoclonal antibody producing hybridomas. In addition, the facility has infrastructure for the production of polyclonal antibodies, as well as laboratories for the synthesis of bioconjugates, haptens, the purification of antibodies and the performance of immunoassays. In addition to the above mentioned equipment, the IQAC-CSIC provides animal husbandry facilities and a unit for the synthesis of organic molecules.

The equipment consists in an inverted phase contrast microscope with a camera, two Class II laminar flow biological safety cabinets, two CO2 incubators, a bioreactor for hybridoma culture, and tangential filtration unit for purification of the antibodies produced in the culture. Among the items of available equipment it should be highlighted a spotter for selection of high antibody producing cell lines and an automated ELISA microplate washer an ELISA reader, two AKTA Prime Liquid chromatography systems for antibody purification, plus standard equipment (centrifuges, fridges, liquid nitrogen containers, autoclave, baths, and vacuum equipment) and all the necessary routine laboratory apparatus. Cabs also has access to a fully equipped chemistry laboratory for the synthesis of haptens and immunoreagents.

The NANBIOSIS Unit 2 works under the ISO9001 certification for standard quality control system QUALITY POLICY

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U2. Services & Rates

Equipments

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 Partner
PICCOLO-732111 Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support European Commission-H2020 H2020-ICT-2016-1 Partner
0624_2IQBIONEURO_6_E Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases European Union Interreg : European Territorial Co-operation POCTEP Interreg España-Portugal Partner

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
PIE1400061 Molecular links between diabetes and neurodegenerative diseases ISCIII Oberver
2014SGR1484 Consolidated Research Group Generalitat de Catalunya Participant
FP7-614168 Real time monitoring of SEA contaminants by an autonomous Lab-on-a-Chip biosensor (SEA-on-a-CHIP) European Commission Oberver
CI16-00031 Caixa Impulse A new approach for the detection of Pseudomonas aeruginosa CaixaBank Participant
MSCA-ITN2015-675412 New Diagnostics for Infectious Diseases European Commission Participant
TECCTP15-1-0011 Ajuda acreditació Tecnio del grup Nb4D ACCIÓ: Generalitat de Catalunya Others

Publications


2016

  • Roncador G., Engel P., Maestre L., Anderson A.P., Cordell J.L., Cragg M.S. et al. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. 2016;8(1):27-36.
  • Pastells C., Pascual N., Sanchez-Baeza F., Marco M.-P.. Immunochemical Determination of Pyocyanin and 1-Hydroxyphenazine as Potential Biomarkers of Pseudomonas aeruginosa Infections. Analytical Chemistry. 2016;88(3):1631-1638.
  • Salvador J.-P., Marco M.-P.. Amperometric Biosensor for Continuous Monitoring Irgarol 1051 in Sea Water. Electroanalysis. 2016;28(8):1833-1838.

News U2

08 Apr

NANBIOSIS to participate in the new edition of the European Biosensors Symposium 2025

NANBIOSIS will join EBS2025 in Tarragona as organizer and sponsor, with a stand to showcase its services in biosensors and nanobiomedicine. Tarragona, october 2025. NANBIOSIS will be actively participating in the European Biosensors Symposium (EBS) 2025, which will take place from 26th to 29th October in Tarragona, Spain. The event, which brings together leading researchers and innovators in the field of biosensors, provides a platform to discuss the latest scientific and technological advances, promote collaboration, and explore new opportunities for innovation. This year, NANBIOSIS is proud to be part of the organization and will also be present as an officia[...]

21 Jun

Prof. Pilar Marco takes helm of CIBER-BBN: Leading the future of Bioengineering, Biomaterials, and Nanomedicine

Barcelona, June 21, 2024 – Prof. Pilar Marco has been appointed as the new head of the Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) thematic area at the Centro de Investigación Biomédica en Red (CIBER). This prestigious appointment was confirmed during the CIBER Governing Board meeting held on June 20, 2024. Prof. Marco succeeds Ramón Martínez, bringing a wealth of expertise and a distinguished track record in biomedical research for more than a decade. Prof. Marco is a research professor at the Consejo Superior de Investigaciones Científicas (CSIC), specifically at the Institute of Advanced Chemistry of Catalonia (IQAC) in Barcelona. Additionally, s[...]

28 Feb

The fight against rare respiratory diseases: New hope in detection and treatment

Researchers from IQAC-CSIC advance towards faster detection and treatment of cystic fibrosis and rare respiratory diseases, improving patient outcomes. 28 February 2024, IQAC-CSIC (Barcelona) Cystic Fibrosis (CF) is a progressive autosomal recessive disease. It is caused by a mutation in the gene encoding the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, disrupting its exocrine activity. While CF affects various organs, its impact on the lungs is particularly severe. This disease leads to the accumulation of thick, sticky mucus, obstructing airways and trapping bacteria, resulting in significant infections and extensive lung damage. Consequently, individuals with CF are highly susceptible to respiratory[...]

24 Nov

From the molecule to the bioassay by Custom antibody service (CAbS)-NANBIOSIS U2 as a PTI+Global Health Infraestructure

During 20-22 of November 2023, the III PTI+Global Health Scientific Conference were held in the Center for Human and Social Sciences, in Madrid. In March 2020, the CSIC (Spanish National Research Council) launched the the Interdisciplinary Thematic Platform (PTI) on Global Health to bring together research teams and enhance knowledge about the new coronavirus SARS-CoV-2, which caused the pandemic. The PTI has mobilized and coordinates more than 400 scientists from 50 CSIC institutes in all areas. The annual PTI+Global Health Scientific Conference are a meeting space where the results of the research carried out in the laboratories can be shown[...]

08 Nov

NANBIOSIS sesion in the CIBER-BBN and CIBEREHD annual meeting. SAFE-N-MEDTECH Project: Outcomes and Future Prospects.

The annual conference of the scientific áreas of CIBER (the most important Centre for Biomedical Research in Spain) are hotly awaited every year for the CIBER community as a foro to be updated about emerging key technologies and discuss about research lines and results, find new opportunities to collaborate and join efforts towards common objectives. Moreover, this year, the Annual Conference of CIBER-BBN (Bioengineering, Biomaterials and Nanomedicine) has been organized as a collective event scheme together with the scientific area of CIBEREHD (Digestive and Liver Diseases). Both areas have already shared experiences of collaborative projects, demonstrating the complementarity of their fields.[...]

20 Oct

The importance of bacterial Quorum Sensing (QS) research recognised in the Princesa of Asturias Awards

Today, Bonnie Bassler, Jeffrey Gordon, and Peter Greenberg are receiving the Princess of Asturias Award for their contribution to the knowledge of the role of the human microbiome and the bacteria Quorum Sensing. Targeting Quorum Sensing allows understanding of bacteria behaviour and pathogenesis, but also developing new therapeutic and diagnostic strategies for infectious diseases. Bonnie Bassler has shown how small chemical signals are involved in such a communication process. Peter Greenberg was one of the first scientists who assigned the term Quorum Sensing (QS) to such a sophisticated system used by bacteria to communicate and synchronize behavior. He was involved[...]

15 May

New look of Nb4D – CAbS (NANBIOSIS U2) “Revolutionising Diagnosis”

Nb4D has a new look on line! Nb4D Group (of IQAC-CSIC and CIBER-BBN) has lunched a new website “Revolutionsising Diagnosis“ with the aim to facilitate a faster and easier navigation througth their “pioneering research to develop new diagnostic and therapeutic approaches” and their solutions and expertise to help researchers and companies. Antibodies, bioreceptors, hapten design and synthesis, immunoanalytical method development, new ivd tools, surface functionalization, therapeutic antibodies and much more knowledge and expertise revolutionising diagnosis. The new website contains a page for CAbS-NANBIOSIS. Custom Antibody Service (CAbS), unit 2 of the ICTS NANBIOSIS[...]

28 Feb

Rare diseases international day 2023: some NANBIOSIS contributions

Today is the international day of rare diseases, a day to raise awareness and instigate change for people living with a rare disease. From NANBIOSIS we want to sume to this celebration and higtligh our commitment to helping people with rare diseases through research. Dr. Ibane Abasolo, Scientific Director of NANBIOSIS U20, was at the WORLDSymposia conference last week in Orlando (FL, USA), where the latest advances in preclinical study and clinic of lysosomal storage diseases were explained. There, she presented the results obtained in the Smart4Fabry project coordinated by the CIBER-BBN where nanoliposomes were developed for the treatment of[...]

U2-Custom Antibody Service (CAbS)
• Read More

U3. Synthesis of Peptides Unit

U3. Synthesis of Peptides Unit

  • Scientific Director: Dr. Miriam Royo miriam.royo@iqac.csic.es
  • Entities: Institute of Avanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
  • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
  • Phone: +34 934 006 100
  • Web: IQAC- CSIC
IQAC CSIC

Order request

U3. Peptides-Automatic synthesizer which can be operated at a range of scalesU3. Peptides-Automatic synthesizer which can be operated at a range of scales
U3. Peptides-System for acidolactic cleavage of the peptide resin boundby anhydrous HFU3. Peptides-System for acidolactic cleavage of the peptide resin boundby anhydrous HF

This Unit is coordinated by the Multivalent Systems for Nanomedicine goup at IQAC-CSIC and has the equipment necessary to provide services of synthesis of peptides at different scales (mg to g), purification, characterization, and post-synthesis modification, such as, conjugation to proteins and fluorescent. It counts with laboratories for synthesis and other to carry out modification of the peptides during and post synthesis labels. Also counts with a laboratory equipped with several preparative and analytical chromatography systems for purification and characterization. This facility benefits from the wide experience of Dr. Fernando Albericio an Dra. Miriam Royo in the design and synthesis of peptides with specific biological activity and the introduction of modifications necessary for these peptides to be bound to therapeutic nanoconjugates and other molecules, either to take advantage of the pharmacological activity of the peptide itself or to facilitate the introduction of nanoconjugates or other molecules into the cells in order to reach the therapeutic target. Its location allows the access to the rest of services of the IQAC-CSIC.

Services

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U3. Services & Rates

Equipments

In addition, this unit has access to:

Active projects

Title Fundin: Organism Call: Funding source Role
ICTS-2017-10-CIBER-2 Acquisition and istallation of infrastrucuture to complemntUnis 3-Synthesis of Peptides, U18-Nanotoxicology y U20-In vivoExperiment Ministerio de Economía, Industria y Competitividad (MINECO) Programa Operativo FEDER de Crecimiento Inteligente 2014-2020 (POCInt) Coordinator
GA: 720942 SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry Unión Europea (Comisión Europea) H2020-NMBP-2016-2017 Coordinator
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017		 Coordinator

Other projects

Ref Title Funding Organism Unit Role
SAF2015-67476-R Immunochemical Strategies of Diagnosis and Therapy based on Quorum Sensing (ImmunoQS) Ministerio de Economía y Competitividad Participant
RTC-2014-2207-1 TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases MINECO Participant

Publications

2016

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U3

29 Jan

A Breakthrough Therapy for Fabry Disease: nanoGLA Demonstrates Promising Results

Fabry disease therapy nanoGLA, developed by NANBIOSIS and our partners, shows superior efficacy in preclinical trials, targeting systemic and brain symptoms. Barcelona, january 2025. An international research team led by the Institute of Materials Science of Barcelona (ICMAB-CSIC) and CIBER-BBN, in collaboration with the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), has developed a groundbreaking nanotechnology-based therapy called nanoGLA for the treatment of Fabry disease. The innovative solution has shown remarkable efficacy in preclinical studies and has been published in the open-access journal Science Advances (see below for reference links). What is Fabry disease? Fabry disease is a rare genetic[...]

09 Oct

Nanotechnology to slow down the growth of glioblastomas

Directors of Unit 20 and Unit 3, Ibane Abasolo and Miriam Royo, show us the ReachGlio project, which uses nanomedicines to slow glioblastoma growth by targeting tumors in the brain, improving drug delivery through nanoparticles. Barcelona, october 2024. Each year, on October 9th, Nanotechnology Day is celebrated, a discipline dedicated to understanding and utilizing matter at a nanometric scale for purposes such as industrial or medical applications. Nanotechnology plays a fundamental role in many research lines developed at the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC) and the Vall d’Hebron Research Institute (VHIR). “Our goal is to propose one or more clinical trials in[...]

08 Nov

Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.

2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed audience. On Tuesday 7 EHD and BBN sessions will specific for each area in separate rooms (with common coffee break). Posters of both areas were on display in the exhibit hall throughout the entirety of the Annual Meeting. Moreover, at the “Posters & beers” session (Monday[...]

20 Jan

New nanoarchitectonics of RGD peptide developed using quatsomes as robust tool in tissue engineering.

Researchers of three groups of CIBER-BBN at CSIC and IBEC, have created a versatile platform based on hierarchically nanostructured RGD peptide using quatsomes, with proved enhanced cell adhesion. These findings, which arose within the framework of the intramural project of CIBER-BBN “Molecular Biointerfaces for cell guidance” (DynaMo4Vasc), open new possibilities for tissue engineering. The participation of two NANBIOSIS units were acknowledged in the publication of the research results: the synthesis of RGD derivatives were performed at NANBIOSIS U3 “Synthesis of peptides unit” of CIBER-BBN at IQAC−CSIC.  And the design and characterization of quatsomes were done at U6 of NANBIOSIS “Biomateria[...]

15 Nov

Happy Day of Chemistry! The role of Chemistry in a sustainable research in health

Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]

27 Jul

1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection

During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]

28 Feb

Fabry Desease in the Rare Disease Day: A New Hope

WHY DO CELEBRATE TODAY THE INTERNATIONAL #RareDiseaseDay? 29 of February is a ‘rare’ date and February, a month with a ‘rare’ number of days, has become a month to raise awareness about rare diseases and their impact on patients’ lives.  Since 2008 thousands of events happen every year all around the world and around the last day of February with the aim of improving equity and reducing stigmatization for people who live with more than 6,000 rare diseases. WHAT ARE RARE DISEASES Rare diseases are pathologies or disorders that affect a small part of the population (less than 5 per 10,000 inhabitants) and[...]

03 Feb

Multivalent self-assembled platforms for the delivery of chemotherapeutic drugs

Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Dr. Miriam Royo, who leads NANBIOSIS unit 3 of Synthesis of Peptide, explains one of the projects in which the ICTS is involved in relation with cancer therapy. The improvement of solubility and stability of clinically approved chemotherapeutic drugs still represent a big[...]

U3-Synthesis of Peptides Unit
• Read More

U6. Biomaterial Processing and Nanostructuring Unit

Ciber bbn

U6. Biomaterial Processing and Nanostructuring Unit

    • Scientific Director: Dr. Mariana Köber mkober@icmab.es
    • Scientific Coordinator:  Dr. Elisabet González Mira egonzalez@icmab.es
    • Technical Coordinator: José Amable Bernabé jabernabe@icmab.es
    • Entities: Instituto de Ciencia de Materiales de Barcelona ICMAB-CSIC
    • Address: Campus de UAB, 08193, Bellaterra, Barcelona, Spain
    • Phone: +34 935 801 853
    • Fax: +34 935 805 729
    • Web: ICMAB

ICMAB CSIC

Order request

U6. Compressed fluids based biomaterials processing platformU6. Compressed fluids based biomaterials processing platform
U6. Dynamic light scattering for particle size and Z potential measurementsU6. Dynamic light scattering for particle size and Z potential measurements
U6. Compressed fluids based biomaterials processingU6. Compressed fluids based biomaterials processing

Description

Located at the Instituto de Ciencia de Materiales de Barcelona (ICMAB-CSIC), in Barcelona, and under the coordination of Prof. Nora Ventosa, current director of NANOMOL Group, which is a research group with wide expertise and recognized excellence in the synthesis, processing, and study of molecular and polymeric materials with chemical, electronic, magnetic and biomedical properties. It gathers several laboratories, perfectly equipped, to perform the mission of this facility: the development, characterization, and large-scale production of molecular biomaterials of therapeutic or biomedical interest, with controlled micro-, nano-, and supramolecular structure. One example of Key-Enabling-Technology (KET) available in this unit is a simple one-step methodology, DELOS-SUSP, based on the use of compressed fluids (CF), such as CO2, to prepare particulate materials with precise and reproducible structural characteristics at micro-, nano- and supramolecular levels (size, shape, internal structural gradients, supra­molecular organization, and crystalline purity). This example shows one of the singularities of this unit: that it counts with CF–based plants at different scales, from mL to L, which allows process development by QbD and process scale-up.
The NANBIOSIS Unit 6 works under the ISO9001 certification for standard quality control system
 




 




 



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE 
		
U6. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







GA: 720942

SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-Fabry
Unión Europea (Comisión Europea)
H2020-NMBP-2016-2017
Coordinator




SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







PI15/00272
Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.
Instituto de Salud Carlos III
Participant




H2020-MSCA-ITN-2014-642196
Integrated self-assembled SWITCHable systems and materials: towards responsive organic electronics - a multi-site innovative training action i-Switch
Unión Europea H2020
Participant




2014 SGR 17
Consolidation Research Group: Molecular Nanociènciai Materials Orgànics (NANOMOL)
Generalitat de Catalunya
Participant




CTQ2013-40480-R
Molecular Bio- and Electro-active materials for the improvement of health and social well-being (Be-Well)
MICINN
Participant




FP7-PEOPLE-2013-ITN nº 607721
Nanochemistry of molecular materials for 2-photon functional applications. Nano2Fun
Unión Europea
Participant




MAT2013-50036-EXP
Cell Surface Vessel Engineering Using Dynamic Molecular Bioinfecting (DYNAMO)
MINECO
Participant




RTC-2016-4567-1
Nanocapsules containing active ingredients for the topical treatment of dermatological diseases (NANO4DERM)
MINECO
Participant




RTC-2014-2183-S
Application of Quatsomes technology for the development of a new range of perfumed softeners with lower environmental impact
MINECO
Participant




201260E080
Self-assembly, Nanostructuring and Processing of Functional Organic Molecules and their Applications
Ministerio de Ciencia e Innovación
Participant




MAT2016-80826-R
Molecular materials and supramolecular organizations for therapy, diagnosis and tissue engineering (MOTHER)
MINECO
Participant




RTC-2014-2207-1
TERARMET: Development of therapies for the treatment of rare congenital metabolic diseases
MINECO
Participant







		

		
Publications

		

			2016


    

  • Munoz-Gomez J.L., Monteagudo E., Lloveras V., Parella T., Veciana J., Vidal-Gancedo J.. Optimized polarization build-up times in dissolution DNP-NMR using a benzyl amino derivative of BDPA. RSC Advances. 2016;6(32):27077-27082.
    • 

  • Cordoba A., Hierro-Oliva M., Pacha-Olivenza M.A., Fernandez-Calderon M.C., Perello J., Isern B. et al. Direct Covalent Grafting of Phytate to Titanium Surfaces through Ti-O-P Bonding Shows Bone Stimulating Surface Properties and Decreased Bacterial Adhesion. ACS Applied Materials and Interfaces. 2016;8(18):11326-11335.
    • 

  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
    • 

  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
    • 




		

		
		
	

		
		
News U6
28 Mar
New hands-on material characterization seminar by NANBIOSIS experts and NANE
Technical Seminar on Materials Characterization by NANBIOSIS Unit 6 & NANE on April 1, 2025, at ICMAB-CSIC. Hands-on training & latest techniques. Register now! Barcelona, march 2025. The Soft Materials Lab – NANBIOSIS Unit 6, in collaboration with NANE, is pleased to invite researchers, professionals, and students to a Technical Seminar on Materials Characterization. The event will take place on Tuesday, April 1st, 2025, from 9:30 AM to 5:00 PM at the Institute of Materials Science of Barcelona (ICMAB-CSIC). This seminar will provide attendees with an opportunity to explore the latest advancements in particle size analysis techniques and gain hands-on[...]
25 Mar
New breakthrough in preventing infections in biomedical implants
A new TPU surface modification with an antimicrobial protein prevents biofilm formation in implants, offering an alternative to antibiotics and metal coatings. Barcelona, february 2025. Infections associated with medical implants are a serious health issue. A new study presents a chemical modification of thermoplastic polyurethane (TPU) with an antimicrobial protein that reduces the formation of biofilms of multidrug-resistant bacteria, offering an alternative to antibiotics and metal coatings in these devices. A team of researchers has developed a new strategy to chemically modify TPU, a material widely used in medical devices, to endow it with antibacterial properties and prevent infections associated[...]
28 Feb
Awareness and research on Fabry Disease with a special event at ICMAB
Join us on April 29 at ICMAB for “Fabry Connections” to explore research, patient insights, and future challenges in Fabry disease. Register now! Barcelona, february 2025. Today, February 28, World Rare Disease Day, NANBIOSIS reaffirms its commitment to advancing research and raising awareness of rare diseases such as Fabry disease. In this context, we are pleased to invite researchers, healthcare professionals, patient associations, and individuals affected by Fabry disease to the event “Fabry Connections: Science, Patients, and Future”, which will take place on Tuesday, April 29, 2025, at the ICMAB-CSIC. This event is organized by our Unit 6, Biomaterial Processing[...]
05 Feb
New Consequences in Familial Hypercholesterolemia due to Abnormal LDL
Misfolded ApoB100 in LDL promotes plaque buildup in familial hypercholesterolemia, raising cardiovascular risk. Structural preservation may aid prevention. Barcelona, febrero 2025. As recently published in the ICMAB webpage, a new study links ApoB100 protein structure (a key protein found in low-density lipoprotein, LDL, often called “bad cholesterol”) to increased cardiovascular risk in familial hypercholesterolemia. The study, led by IIBB-CSIC and CIBER, with the contribution of ICMAB’s SOFT Service (with NANBIOSIS Unit 6 at its core), shows that the protein structure directly contributes to an increased tendency to aggregate and form atherosclerotic plaques in patients with familial hypercholesterolemia. In these patients,[...]
29 Jan
A Breakthrough Therapy for Fabry Disease: nanoGLA Demonstrates Promising Results
Fabry disease therapy nanoGLA, developed by NANBIOSIS and our partners, shows superior efficacy in preclinical trials, targeting systemic and brain symptoms. Barcelona, january 2025. An international research team led by the Institute of Materials Science of Barcelona (ICMAB-CSIC) and CIBER-BBN, in collaboration with the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), has developed a groundbreaking nanotechnology-based therapy called nanoGLA for the treatment of Fabry disease. The innovative solution has shown remarkable efficacy in preclinical studies and has been published in the open-access journal Science Advances (see below for reference links). What is Fabry disease? Fabry disease is a rare genetic[...]
23 Oct
attendants of the course held at ICMAB
The Soft Lab held a new edition of the course on characterization and preparation of particulate materials
José Amable Bernabé, Technical Coordinator of Unit 6, hosted a course on “Characterization techniques for particulate materials”. Barcelona, october 2024. For yet another year, José Amable Bernabé, of the Soft Materials Service at ICMAB and Technical Coordinator of NANBIOSIS Unit 6, offered this course. The course was an explanation of different techniques to characterize nanoparticles and particulate matter, including the fundamentals of these techniques, sample preparation, practical examples and results interpretation. The course is offered every year through the CSIC training courses offered every year for all its staff, as reported in ICMAB webpage. Soft Materials Service The Soft Materials Service provides[...]
01 Mar
Reaching for the unreachable: New efforts to treat Lysosomal Storage Diseases
NANBIOSIS researchers pioneer novel treatments for Lysosomal Storage Diseases utilizing extracellular vesicles and liposomes, offering hope to patients. 1 March 2024, Vall d’Hebron Research Institute/ICMAB-CSIC (Barcelona) Lysosomal Storage Diseases (LSDs) encompass a group of rare disorders caused by mutations in lysosomal proteins. These mutations can lead to dysfunctional proteins responsible for breaking down cellular materials, resulting in the accumulation of deposits. Such accumulations can manifest in various neurological symptoms, ranging from progressive neurodegeneration to severe cognitive impairment. Often emerging in childhood, LSDs tragically culminate in premature death for many patients. Currently, up to 14 subtypes of LSDs can be treated[...]
21 Feb
The NABIHEAL Project Pioneers Wound Healing with New Biomimetic Matrices
Nearly 40 scientists across 7 countries are pioneering this breakthrough in wound healing using a nobel and affordable bio-inspired, anti-bacterial matrix. In addition to the vast consortium, the project also comprises 5 small and medium-sized enterprises (SMEs) and 9 academic institutions. These were convened last February at the University of Granada to share insights, progress, and strategies. According to an article published by UGR at the beginning of this month, about 40 researchers involved in the project have attended a meeting to share results and progress. The Horizon Europe project NABIHEAL, coordinated by the Biomedical Research Networking Center (CIBER) at[...]

		
		
	

											

											U6-Biomaterial Processing and Nanostructuring Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U7. MicroFab & Microscopy Unit

												


		
		

		
		
	

		
		
Ciber bbn





U7. MicroFab & Microscopy Unit
















 


Order request

		
		
	

		
		
U7. Nanotechnology PlatformU7. Nanotechnology Platform
U7. Nanotechnology-PMMA surface with micro and nanostructures by e-beam lithographyU7. Nanotechnology-PMMA surface with micro and nanostructures by e-beam lithography
U7. Nanotechnology-Using photolitography to fabricate microfluidic devicesU7. Nanotechnology-Using photolitography to fabricate microfluidic devices


Description


The MicroFab & Microscopy Platform is part of the institute’s long-term strategic plan to create new Core Facilities in nanofabrication and bionanocharacterization. Currently, the platform is an accessible and versatile research facility featuring 150m2 of class 10,000 cleanroom space and laboratories offering state-of-the-art equipment for the fabrication and characterization of micro- and nanodevices and structures. Our aim is to facilitate advanced research by providing services in the fields of nanoscience and nanotechnology for all academic and industrial researchers. Some of the many areas of application include nanobioengineering, BioMEMS, materials science, tissue engineering, optic and biomaterials. IBEC’s Nanotechnology Platform offers scientific and technological support that includes the design, development and analysis of devices, materials, and processes, so that academic researchers and companies alike may use the platform to develop their innovative ideas.







		
Services

		

			


FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE


		
U7. Services & Rates

		
Equipments

		

			


		

		
		
	

		
		

		
Active projects

		

			
TitleFundin: OrganismCall: Funding source Role

    
    
	
	
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Partner
PICCOLO-732111Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision supportEuropean Commission-H2020H2020-ICT-2016-1Partner
0624_2IQBIONEURO_6_EPromotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseasesEuropean Union Interreg : European Territorial Co-operationPOCTEP Interreg España-PortugalPartner

    


		

		
Other projects

		

			
RefTitleFunding OrganismUnit Role

    
    
	
	
TEC2015-70104-PMicroscrofidic 3D platform of Neuronal culture compartmentalized for the study of neurological diseasesMINECOOthers
COMRDI15-1-0013-09Advancecat: acceleradora pel desenvolupament de terapies avançadesACCIÓParticipant

    


		

		
Publications

		

			2016


    

  • Lagunas A., Tsintzou I., Vida Y., Collado D., Perez-Inestrosa E., Pereira C.R. et al. Tailoring RGD local surface density at the nanoscale toward adult stem cell chondrogenic commitment. Nano Research. 2016;:1-13.
    • 



		

		
		
	

		
		
News U7
14 Mar
Hamill Industries visits NANBIOSIS during new artistic residency
Hamill Industries visited NANBIOSIS Unit 7 at IBEC, merging art and nanotech through the Ciència Radical program to inspire new audiovisual creations. Barcelona, march 2025. Last week, the Institute for Bioengineering of Catalonia (IBEC) had the pleasure of welcoming the renowned visual artist collective, Hamill Industries, as part of the Ciència Radical artistic residency program. This initiative, co-organized by IBEC, the Centre de Cultura Contemporània de Barcelona (CCCB), IFAE, ICFO, and ALBA Synchrotron, aims to foster interdisciplinary collaboration between scientists and artists, exploring radical science through audiovisual works. During their visit, Hamill Industries explored several cutting-edge research laboratories, including MicroFab[...]
24 Oct
NANBIOSIS U7 at the 15th IBEC Symposium October 2022
The MicrofabSpace and Microscopy Characterization Facility of IBEC, U7 unit of Nanbiosis, presented a stand and posters in the 15 edition of the annual IBEC’s Symposium which took place last October 19th in Barcelona. Researechers of this facility showed new microfabrication processes and microscopy tools, to worldwide researchers in the field of bioengineering. The MicroFabSpace and Microscopy Characterization Facility is one of the most experienced services in the IBEC’s Core Facilities. With a cleanroom research space, specialized in the microfabrication and characterization of micro-structured devices focussed on bioengineering and a microscopy space specialized in the characterization of biological samples, it[...]
27 Jul
1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection
During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]
16 Sep
Microfluidic devices: The process of development
The development of microfluidic devices is very significant for in-vitro diagnostic devices, biomarkers and organ-on-a-chip applications. The techniques, the materials and the equipment used for the fabrication of these devices, are as important as the strategy followed to obtain them. And at the Nanotechnology unit of NANBIOSIS U7– (MicrofabSpace and Microscopy Characterization Facilities of IBEC), we own the tools, the know-how and the expertise to accomplish such a goal. We regularly guide the process of design, in collaboration with the final user, we customize the technology needed to get the product and complete the fabrication of the microfluidic device, drawing[...]
16 May
The importance of Nanomedicine and Bioengineering to address health challenges
Josep Samitier, Coordinator of the Nanomedicine Platform (NanoMed) and Director of IBEC, as well as Scientific Director of NANBIOSIS unit 7 of Nanotecnology, of IBEC and CIBER-BBN, particiated in the XIV Annual Conference of Biomedical Research Technology Platforms was held on 11 and 12 May. The Conference counted with the presence of relevant public and private sector actors, and more than 700 registered participants. During the opening ceremony, was opened, among others, by the Minister of Science and Innovation, Pedro Duque, it was precisely emphasized the importance of investment in science and technology. In the words of Josep Samitier: “The healt[...]
11 Feb
NANBIOSIS Scientific Women in the International Day of Women and Girls in Science
Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribut[...]
22 Jul
The Scientific Director of NANBIOSIS Unit 7, awarded with the Narcís Monturiol medal for his contribution to science and technology
The Catalan Government announced yesterday the Narcís Monturiol Medal award for scientific and technological merit to the Director of NANBIOSIS Unit 7 Nanotechnology Unit from CIBER-BBN and IBEC, Josep Samitier Martí, for his contribution to the development of the Catalan system of science and technology. The Narcís Monturiol Prize was established by the Generalitat of Catalonia in 1982, in honor of the Catalan scientist and inventor Narciso Monturiol, to award the people and entities that have made an outstanding contribution to the scientific and technological progress of Catalonia. It is awarded in the form of medals and plaques. The medals[...]
08 Jun
NANBIOSIS researchers featured in the 15th Edition of Spanish Researchers Ranking
The 15th edition of the Webometrics Ranking of World Universities has been published, ranking researchers in Spain as well as Spaniards doing research abroad. A total of 11 Directors of NANBIOSIS units appear on the most recent list, featured on the top 2000. The list is ordered by the h-index, a metric that calculates research impact based on a correlation of papers published and number of citations, and then by number of citations. The result is a list of whose’s publications have had more impact online. NANBIOSIS researchers featured are Fernando Albericio (#207), scientific director of U3 Synthesis of Peptides[...]

		
		
	
											

											U7-Nanotechnology Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U8. Micro – Nano Technology Unit

												

		
		

		
		
	

		
		
Ciber bbn


U8. Micro – Nano Technology Unit


    

  • Scientific Director: Dr. Rosa Villa rosa.villa@imb-cnm.csic.es
    • 

  • Scientific Coordinator: Dr. Xavier Illa xavier.illa@imb-cnm.csic.es
    • 

  • Entities: Instituto de Microelectrónica de Barcelona – Centro Nacional de Microelectrónica (IMB-CNM, CSIC)
    • 

  • Address: Campus UAB, 08193, Cerdanyola del Vallés, Barcelona, Spain
    • 

  • Phone: +34 935 947 700 ext. 1208
    • 

  • Web: IMB – CNM, CSIC
    • 









CNM
CSIC






Order request

		
		
	

		
		
U8 MicroNanotechnology Unit..U8 MicroNanotechnology Unit..
U8 MicroNanotechnologyU8 MicroNanotechnology
U8-MicroNanotechnology-Unit-_c3U8-MicroNanotechnology-Unit-_c3


Description


This Micro-Nano Technologies Unit is located in the Microelectronic Institute of Barcelona, (IMB-CNM, CSIC) and it is coordinated by Dr. Rosa Villa.


The unit has the capacity for producing high quality CVD-graphene and, thanks to the integration of the unit in the clean room facilities of the IMB-CNM, it is possible to complete a wide range of micro- and nanofabrication processes (thermal processes and CVD, metallization, photolithography, dry and wet etching, etc.) for the complete fabrication of graphene-based microdevices. The unit also comprises the equipment that allow the fabrication of such devices in flexible substrates like Polyimide and Parylene to build biocompatible implants and neuroprosthesis. In addition, the unit has the capacity for the encapsulation and electrical characterization of the fabricated devices.


The clean-room facility of the IMB-CNM is the largest installation with micro-nano technologies facilities in Spain. Its 1500 m2 Clean Room classes 10 to 10,000 are part of the MICRONANOFABS network, considered as Singular Scientific-Technical Infrastructure (ICTS).





		
Services

		

			



.


FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U8. Services & Rates

		
Equipments

		

			



.


Furthermore, in the IMB-CNM clean room (1500 m², Classes 10 to 10,000), there is also the following equipment, which is accessible under its own access policy:




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







GA: 696656



Graphene-based disruptive technologies — GrapheneCore1


Unión Europea (Comisión Europea)
H2020-Adhoc-2014-20
Partner




GA: 785219

Graphene Flagship Core Project-2 — GrapheneCore2’

’		
Unión Europea (Comisión Europea)
H202-SGA-FET-GRAPHENE-2017
Partner




GA: 649953

GRAPHENE FPA – FLAGSHIP - Graphene-based revolutions in ICT and beyond
Unión Europea (Comisión Europea)
H2020-FETFLAG-2014
Partner




SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







SAF2014-62114-EXP
RUPTURE OF THE HEMATORRETINIAN BARRIER: CAUSE OR CONSEQUENCE OF THE DIABETIC RETINOPATHY?
MINECO
Others




BIO2014-61377-EXP
BIOLIVER: THE DECONSTRUCTION APPLIED TO HEPATOLOGY
MINECO
Others




H2020-Adhoc-2014-20 - 696656
GrapheneCore1
European Commission
Participant




FP7-ICT-2013-FET-F - 604391
Neurographene: Neurological Recordings with Graphene
EUROPEAN COMISSION
Others




IMI Grant agreement No 115902
Remote Assessment of Disease and Relapse in Central Nervous System Disorders (RADAR-CNS)

Others







		

		
Publications

		

			2016


    

  • Moya A., Sowade E., del Campo F.J., Mitra K.Y., Ramon E., Villa R. et al. All-inkjet-printed dissolved oxygen sensors on flexible plastic substrates. Organic Electronics: physics, materials, applications. 2016;39:168-176.
    • 

  • Yeste J., Illa X., Gutierrez C., Sole M., Guimera A., Villa R.. Geometric correction factor for transepithelial electrical resistance measurements in transwell and microfluidic cell cultures. Journal of Physics D: Applied Physics. 2016;49(37):-.
    • 

  • Hernando A., Lazaro J., Gil E., Arza A., Garzon J.M., Lopez-Anton R. et al. Inclusion of Respiratory Frequency Information in Heart Rate Variability Analysis for Stress Assessment. IEEE Journal of Biomedical and Health Informatics. 2016;20(4):1016-1025.
    • 




		

		
		
	

		
		
News U8
21 Oct
A project on pediatric respiratory infections, led by NANBIOSIS, wins the CIBER Young Researcher Call
Chips R’ Us, a pediatric respiratory infection study, wins CIBER’s Young Researcher Call, developing an innovative lung model using Organ-on-Chip technology. Vigo, october 2024. The project Chips R’ Us, focused on studying lower respiratory infections in pediatric patients, has been selected in the 2024 Call for Intramural Projects for Young Researchers of the Biomedical Research Networking Center (CIBER). An evaluation board composed of specialists from various CIBER thematic areas evaluated the proposals based on their novelty, feasibility, interdisciplinary collaboration, and potential social impact. Led by Dr. Gabriel Alfranca, a researcher in the area of Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN) at[...]
08 Mar
The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024
Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation. March 8th 2024, NANBIOSIS (Spain) Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper[...]
18 Jul
ICTS participation in the First guide to facilitate the sustainable design of printed electronic devices
Scientists of NANBIOSIS Unit 8 have participated in the publication of a a comprehensive experimental review of inks, paper substrates, and printing techniques. The objective is to offer the scientific community a guide with data to facilitate the design of printed devices and manufacture them in an ecological way. Gemma Gabriel, researcher of Biomedical Applications Group at IMB-CNM and last author of the article, highlights the applications of the results in health monitoring, with non-invasive techniques such as glucose detection, although there are many applications where printed electronic materials and technologies are very useful. Among them, environmental monitoring, (in air[...]
03 Feb
“CIBER is collaboration”
CIBER Centro de Investigación Biomédica en Red (Consortium for Biomedical Research Network), one of the ICTS NANBIOSIS nodes to which 18 of its 26 units belong, presents the new institutional video “CIBER is Collaboration” This video puts a face to the scientific activity of CIBER researchers and highlights CIBER capacity for synergy. CIBER researchers speak about the main research lines of its 13 subject areas and highlights the collaboration between its more than 500 groups and more than 6,000 researchers belonging to more than 100 institutions of different natures that make up CIBER: hospitals, research centers, universities, foundations, etc. T[...]
25 May
“The almighty graphene”,  a podcast by Elisabet Prats
Elisabet Prats Alfonso, a researcher in the team coordinating NANBIOSIS U8 Micro– Nano Technology Unit explains in a podcast her most recent research based on the functionalization of chemical and biochemical sensor platforms as well as the characterization of materials such as graphene for both neuronal recording and biomarker detection. Her work is part of the Graphene Flagship project in which she collaborates with relevant European groups. Eli Prat as a researcher Ph.D. in Chemistry and also dedicated to dissemination is a great exemple for the NANBIOSIS aim to encourage STEAM scientific vocations especially among girls. In addition, she is[...]
07 Apr
Researchers of NANBIOSIS U8 highlighted in the World Health Day
In the Picture: Gemma Gabriel and Rosa Villa World Health Day is celebrated every year on 7 April (on the aniversary of the World Health Organization constitution) to raise awareness about the ongoing health issues that concern people across the world. This year, Xarctec Salud has called the attention on patients with brain diseases and spinal cord injuries and has highlighted the GAB Lab. Biomedical Applications Group of the IMB-CNM-CSIC and CIBER-BBN, the group, led by Rosa Villa, coordinates unit 8 ICTS NANBIOSIS of Micro-nano Technology Unit. https://youtu.be/wiA5oFc6Q48 The Xartec Salut is a network, led by CREB UPC, made up of 47[...]
07 Jan
New graphene-based neural probes improve detection of epileptic brain signals
A study published in Nature Nanotechnology shows that flexible brain probes made of graphene micro-transistors can be used to record pathological brain signals associated with epilepsy with excellent fidelity and high spatial resolution. This research was led by the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the University College London Queen Square Institute of Neurology (UK). The ability to record and map the full range of brain signals using electrophysiological probes will greatly advance our understanding of brain diseases and aid the clinical management of patients with diverse neurological disorders. However, current technologies[...]
23 Dec
The  suitability of flexible graphene depth neuralprobes for in vivo electrophysiology research
A study published in “Nature Nanotechnology” shows that flexible brain probes made of graphene micro-transistors can be used to record pathological brain signals associated with epilepsy with excellent fidelity and high spatial resolution. This research was led by the Catalan Institute of Nanoscience and Nanotechnology (ICN2), the Institute of Microelectronics of Barcelona (IMB-CNM-CSIC) and the University College London Queen Square Institute of Neurology (UK). Barcelona, Wednesday 22 December 2021. The ability to record and map the full range of brain signals using electrophysiological probes will greatly advance our understanding of brain diseases and aid the clinical management of patients wit[...]

		
		
	

											

											U8-Micro-Nano Technology Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U9. Synthesis of Nanoparticles Unit

												

		
		
Ciber bbn


U9. Synthesis of Nanoparticles Unit




    

  • 

      

    • Entities: Instituto de Materiales y Nanociencia de Aragón (INMA)
      • 

    • Address: R&D Building, Campus Río Ebro, Universidad de Zaragoza. C/Mariano Esquirl S/n, 50018, Zaragoza, Spain
      • 

    

    • 



    

  • 



    

  • 

      

    • Phone: 34 976 761000 ext. 3496
      • 

    

    • 




 Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27.


Order request

		
		
	

		
		
U9. Synthesis of Nanoparticles- plasmonic nanoparticles 1U9. Synthesis of Nanoparticles- plasmonic nanoparticles 1
U9. Synthesis of Nanoparticles- hollow magnetic nanoparticlesU9. Synthesis of Nanoparticles- hollow magnetic nanoparticles
U9. Synthesis of Nanoparticles- Laser pyrolysis device and reaction areaU9. Synthesis of Nanoparticles- Laser pyrolysis device and reaction area


Description


This unit, integrated in the Nanostructured Films and Particles Group at the Institute of Nanoscience and Materials of Aragón (INMA) coordinated by Dr. Jesús Santamaría, has as objective the synthesis of nanoparticles with applications in biomedicine. The unit provides an automated system for the synthesis of nanoparticles using laser-induced pyrolysis of chemical precursors in gas and/or aerosol phase, which enable either individual nanoparticles or biocompatible hybrid nanostructures to be produced in large quantities. In addition, this facility is able to draw on a wide range of nanoparticles fabrication technique, as well as having the necessary specialized personnel, to undertake exhaustive characterization of the microstructure, chemical composition, particles size and distribution of sizes, as well as magnetic, optical and colloidal properties and degree of biological functionality of the synthesized material.



		
Services

		

			


FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE


		
U9. Services & Rates

		
Equipments

		

			


In addition to this there is immediate access to advanced electron microscopies (SEM, TEM, HRTEM, UHRTEM), as well as other surface analysis and characterization equipment (XPS, XRD, FTIR, magnetic characterization). The equipment available makes this Unit unique to produce a wide variety of nanoparticles, , inorganic, polymeric, or multifunctional hybrid nanocomposites. 
		

		
		
	

		
		

		
Active projects

		

			
TitleFundin: OrganismCall: Funding source Role

    
    
	
	
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Partner
PICCOLO-732111Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision supportEuropean Commission-H2020H2020-ICT-2016-1Partner
0624_2IQBIONEURO_6_EPromotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseasesEuropean Union Interreg : European Territorial Co-operationPOCTEP Interreg España-PortugalPartner

    


		

		
Other projects

		

			
RefTitleFunding OrganismUnit Role

    
    
	
	
CTQ2014-52384-RINTELLIGENT APPLICATIONS BASED ON NANOSTRUCTURED FIBERS CONTAINING NATURAL BIOCIDES WITH PHARMACOKINETIC CONTROL OF THEIR RELEASEMinisterio de Economia y CompetitividadParticipant
CTQ2013-49068-C2-1-RMICROSYSTEMS BASED ON NANOSTRUCTURES WITH SPECIFIC PROPERTIES OF ADSORPTION AND SUPERFICIAL PLASMON, FOR DETECTION OF HIDDEN EXPLOSIVES AND AGENTS OF CHEMICAL WAR.Ministerio de Economia y CompetitividadParticipant
TARMACTARMAC. New tools for the diagnosis and treatment of respiratory infectious diseases: pH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistenceMinisterio de Economia y competitividadParticipant
TARMAC/IQMA-UDM-UPVpH-responsive matryoshka nanoparticles for an efficient and controlled intracellular delivery of oral antibiotics and gated nanoparticles for the detection of pathogenic microorganisms showing intracellular persistenceCIBER-BBN-CIBERES-SEPARParticipant
H2020-MSCA-ITN-2016/H2020-MSCA-ITN-2016European Training Network for Continuous Sonication and Microwave Reactors.Unión EuropeaParticipant
H2020-SPIRE-2014-2015 ADREM / Adaptable Reactors for Resource- and Energy-Efficient Methane ValorisationUnión EuropeaParticipant
I-2012/023Development of a microfluidic platform to produce nanomaterials and assessment on new nanotechnology applicationsUnión EuropeaParticipant
CTQ2016-77147-RNEW STRATEGIES FOR CO2 CONVERSION USING CATALYSTS UNDER ELECTROMAGNETIC RADIATION.MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDADParticipant
CTQ2016-79419-RADVANCED ADSORPTION TECHNOLOGIES, SERS DETECTION AND CATALYSIS FOR CHEMICAL WARMINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDADParticipant
NANOHEDONISMA photo-triggered on-demand drug delivery system for chronic painEuropean Research CouncilParticipant
I-2011/004HECTOR- MICROWAVE-ASSISTED MICROREACTORS: DEVELOPMENT OF A HIGHLY EFFICIENT GAS PHASE CONTACTOR WITH DIRECT CATAYST HEATINGUnión EuropeaParticipant
FIS PI15/01118Towards an advanced therapy of bone regeneration: tissue intermediates activated by infrared energy for the controlled expression of osteogenic and angiogenic factorsINSTITUTO DE SALUD CARLOS IIIOthers
AMBITAnimal Model of Bone Regeneration Induced by Tissue Intermediates Responsive to Near-Infrared LightRoche FarmaParticipant

    


		

		
Publications

		

			2016


    

  • Sebastian V., Smith C.D., Jensen K.F.. Shape-controlled continuous synthesis of metal nanostructures. Nanoscale. 2016;8(14):7534-7543.
    • 



		

		
		
	

		
		
News U9
14 Feb
New Dendritic Platinum Nanocatalysts for Selective Activation of Anticancer Drugs
PEGylated dendritic platinum nanoparticles enable targeted drug activation, reducing tumors in vivo. Developed with NANBIOSIS Unit 9, they enhance cancer therapy. Zaragoza, february 2025. A recent study published in Angewandte Chemie International Edition (see reference at the end of the article) introduces a novel approach in cancer treatment through the development of PEGylated dendritic platinum nanoparticles. These nanoparticles exhibit high biocompatibility and selectively activate anticancer drugs within cancer cells. The study was co-led by members of the Nanostructured Films and Particles (NFP) group, Dr. Jose I. Garcia-Peiro, Dr. Jose L. Hueso and Prof. Jesus Santamaria (Group Leader) that belong to CIBER-BBN, t[...]
26 Dec
Innovative Copper-Based Nanoparticles Open New Frontiers in Glioblastoma Treatment
NANBIOSIS Unit 9 advances glioblastoma treatment with tailored copper nanoparticles, reducing tumor invasiveness and opening new therapeutic pathways. Zaragoza, December 2024. Our Unit 9, specialized in nanoparticle synthesis, has achieved a breakthrough in the fight against glioblastoma, one of the most aggressive and treatment-resistant forms of cancer. Utilizing state-of-the-art facilities and expertise, the Unit and its collaborators have developed novel copper-based nanostructures with tailored release patterns, demonstrating significant potential in inhibiting tumor progression and invasiveness. A New Paradigm in Cancer Therapy Glioblastoma (GBM) is characterized by its high invasiveness and poor prognosis. Current therapeutic options are limited by the tumor’s[...]
25 Nov
New Solutions to Old challenges: Key Symposium on Nanomedicine Against Cancer
Symposium on nanomedicine vs cancer: experts gather Nov 28 in Málaga to tackle tumor-targeting challenges and advance innovative therapies. Málaga, november 2024. On November 28th at 9:00 AM, the Salón de Actos at IBIMA (C/Severo Ochoa, 35, Málaga) will host the symposium “Targeting in Nanomedicine Against Cancer,” bringing together leading experts to discuss the critical challenges and advances in applying nanomedicine to oncology. Organized by IBIMA, this event will shed light on one of the most pressing issues in cancer nanomedicine: the difficulty of delivering nanostructures to tumor cells. The challenges to overcome cancer Cancer remains one of the world’s[...]
22 Nov
Jesús Santamaría awarded with the ‘Aragón Investiga’ for his Research Excellence
Prof. Jesús Santamaría, Director of NANBIOSIS Unit 9, wins the Aragón Investiga Award for his pioneering contributions to nanomaterials and research excellence. Zaragoza, november 2024. The Aragón Investiga Award for Research Excellence has been awarded to Prof. Jesús Santamaría Ramiro, a distinguished researcher and Full Professor of Chemical Engineering at the University of Zaragoza, and Scientific Director of Unit 9 of NANBIOSIS. Prof. Santamaría is the principal investigator of the Nanostructured Films and Particles group, where Unit 9 is located. He is also a key member of the Institute of Nanoscience and Materials of Aragón (INMA), a Severo Ochoa Center[...]
25 Sep
Latest breakthroughs in pulmonary drug delivery and cancer research at NANBIOSIS
On World Pharmacists’ Day, NANBIOSIS Units highlighted for breakthroughs in pulmonary drug delivery and cancer research, advancing treatments for respiratory diseases and brain cancer. Barcelona and Zaragoza, September 2024. On World Pharmacists Day, we celebrate the vital contributions pharmacists make, not only in patient care but also in groundbreaking research that is shaping the future of healthcare. This year 2024, we want to give this significant date a little twist: by showcasing a few examples of how our Units are contributing to healthcare and new pharmaceutical approaches. Two key NANBIOSIS units —Unit 9 and Unit 25— are at the forefront[...]
09 Apr
New cathalitic therapy for destroying key molecules within tumor cells
The prestigious journal Nano Letters published the work led by NANBIOSIS researchers, affiliated with Unizar, INMA (CSIC-UNIZAR), CIBER–BBN, and IIS Aragón. The successful development of this innovative treatment approach was possible through the efforts of our Unit 9, led by Prof. Santamaría and Dr. Hueso, both corresponding authors of the publication. As recently announced by Universidad de Zaragoza (Unizar), a team led by NANBIOSIS researchers at the Instituto de Nanociencia y Materiales de Aragón (INMA, a joint institute of CSIC and UNIZAR) has discovered a way to artificially conduct a new chemical reaction, called transamination. This approach can act within[...]
08 Mar
The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024
Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation. March 8th 2024, NANBIOSIS (Spain) Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper[...]
26 Feb
Women in NANBIOSIS part 4: María Sancho’s journey from nanomaterials to cancer therapy
Our expert in nanocarriers talks about her journey from biotechnology to cancer therapy, an example of passion and perseverance in science. February 2024, I3A/CIBER-BBN, Zaragoza (Spain) The silence of the meeting room is only broken by the constant purring of the heating system. A large square table made of dark wood fills the entire room almost completely. Its dimensions are too extensive for anyone to reach its center. One may wonder, how many passionate conversations about the next step to take in countless research projects have been witnessed by these four walls? The door swings open briskly, and a familiar[...]

		
		
	

											

											U9-Synthesis of Nanoparticles Unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U10. Drug Formulation

												

		
		
Ciber bbn


U10. Drug Formulation


    

  • 

      

    • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
      • 

    • Scientific Coordinator: Dr. Idoia Gallego Garrido idoiagallego@hotmail.com
      • 

    • Entities: Universidad del País Vasco (UPV/EHU)
      • 

    • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
      • 

    • Phone: +34 653593042
      • 

    • Fax: +34 945 013040
      • 

    • Web: NANOBIOCEL UPV/EHU
      • 

    

    • 









UPV-EHU






Order request

		
		
	

		
		
U10. Drug Formulation-Particle_size_analyzerU10. Drug Formulation-Particle_size_analyzer
U10. Drug Formulation-LOTE 4 CALCEINA 10X 2BISU10. Drug Formulation-LOTE 4 CALCEINA 10X 2BIS
U10. Drug Formulation- Dissolution_rate_determination_equipmentU10. Drug Formulation- Dissolution_rate_determination_equipment


Description


Located at the Faculty of Pharmacy, University of the Basque Country (UPV/EHU), Campus of Alava in Vitoria. The Unit is led by Prof. José Luis Pedraz and consists of large laboratories for cell culture, chromatography equipment, sample preparation and characterization, and one specific for scale preparation of pharmaceutical formulations. Recently the group has incorporated 3D bioprinters of the last generation with different technologies based on extrusion, inkjet, among others. It has also incorporated self-assembly equipment of nanoparticles based on microfluidic technologies.


This Unit can design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA, and vaccines using different methodologies based on micro and nano-medicine and the latter technology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this Unit. It counts on the most advanced equipment for micro and nanoencapsulation.


The Unit aims to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.


The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit10 counts with the most advanced equipment to cover the development for all the steps of the process.


One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency 



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE



		
U10. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


    

  • Inhaled RNA Vaccines Against Tuberculosis. RTC: PMPTA/00143. Call: “Proyectos de I+D vinculados a la medicina personalizada y terapias avanzadas” from the joint initative ISCIII-CDTI. Funding agency: EU Next Generation Ministerio de Ciencia e Innovación CDTI. Duration: May 2024 – May 2026. Role: Partner.
    • 

  • Nanovectors for direct local-regional and controlled intravenous administration of antitumor drugs. Strategies to minimize adverse effects and maximize therapeutic response. ONCOLIBERYX. RTC: CPP2021-008362. Call: Convocatoria de ayudas para proyectos de colaboración público-privada 2021. Funding agency: Ministerio de Ciencia e Innovación. Duration: May 2022 – May 2024. Role: Partner.
    • 

  • Unlocking data content of Organ-On-Chips UNLOOC. RTC: 101140192-1. Call: HORIZON-KDT-JU-2023-1-IA-Topic-1. Funding agency: HORIZON Programme. Duration: January 2023 – May 2024. Role: Partner.
    • 

  • Optimization of a non-viral vector platform based on functionalized niosomes with nanodiamonds for gene therapy in cystic fibrosis. IP: Jose Luis Pedraz Muñoz and Gustavo Puras Ochoa. Funding agency: Ministerio de Ciencia e Innovacion. Funds: € 181.500. Duration: Jun 2020 – Jun 2023
    • 




		

		
Other projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







RTC-2016-4770-1

Development of a new bioadhesive for the treatment of Pterigium. Biotape


Ministerio de Economía, Industría y Competitividad (MINECO)
Retos Colaboración 2016
Partner




RTC-2016-5451-1

Development of Bioprinting and Bioink systems for cartilage and bone repair


Ministerio de Economía, Industria y Competitividad (MINECO)
Retos Colaboración 2016
Partner




GA: 783132

POSITION-II “A pilot line for the next generation of smart catheters and implants”


Electronic Component Systems for European Leadership Joint Undertaking (JU) - ECSEL JU
H2020-ECSEL-2017-1-IA-two-stage
Partner




GA: 645991

DRIVE – Diabetes-Reversing Implants for Enhanced viability and long-term efficacy
Unión Europea (Comisión Europea)
H2020-NMP-2014-two-stage
Partner




SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización  «REDES DE EXCELENCIA»

-ICTS 2017		
Coordinator






	




Ref
Title
Funding Organism
Unit Role







RTC-2016-4770-1
DEVELOPMENT OF A NEW BIOADHESIVE FOR PTERIGIUM SURGERY. BIOTAPE
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD.
Participant




RTC-2016-5451-1
DEVELOPMENT OF BIOIMPRESSION SYSTEMS AND BIOTINES FOR THREE-DIMENSIONAL CARTILAGE AND BONE REGENERATION
MINISTERIO DE ECONOMIA, INDUSTRIA Y COMPETITIVIDAD.
Participant




RTC-2015-3303-1
Lipid solid nanoparticles for subcutaneous administration of antitumor marine compounds - UNDERLIPIDS
MINISTERIO DE ECONOMIA Y COMPETITIVIDAD








		

		
Publications

		

			2016


    

  • Grijalvo S., Puras G., Zarate J., Pons R., Pedraz J.L., Eritja R. et al. Nioplexes encapsulated in supramolecular hybrid biohydrogels as versatile delivery platforms for nucleic acids. RSC Advances. 2016;6(46):39688-39699.
    • 

  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Fleischer A. et al. Pulmonary delivery of tobramycin-loaded nanostructured lipid carriers for Pseudomonas aeruginosa infections associated with cystic fibrosis. International Journal of Pharmaceutics. 2016;498(1-2):263-273.
    • 

  • Moreno-Sastre M., Pastor M., Esquisabel A., Sans E., Vinas M., Bachiller D. et al. Stability study of sodium colistimethate-loaded lipid nanoparticles. Journal of Microencapsulation. 2016;33(7):636-645.
    • 

  • Garcia-Orue I., Gainza G., Gutierrez F.B., Aguirre J.J., Evora C., Pedraz J.L. et al. Novel nanofibrous dressings containing rhEGF and Aloe vera for wound healing applications. International Journal of Pharmaceutics. 2016;:-.
    • 

  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The role of helper lipids in the intracellular disposition and transfection efficiency of niosome formulations for gene delivery to retinal pigment epithelial cells. International Journal of Pharmaceutics. 2016;503(1-2):115-126.
    • 

  • Ojeda E., Puras G., Agirre M., Zarate J., Grijalvo S., Eritja R. et al. The influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain. Biomaterials. 2016;77:267-279.
    • 




		

		
		
	

		
		
News U10
10 Apr
Innovative eye drops offer new hope for Retinitis Pigmentosa patients
NANBIOSIS Unit 10 helps develop eye drops with adalimumab for retinitis pigmentosa, showing promising results in preclinical models. Vitoria, april 2025. A multidisciplinary team of researchers from the Centro de Investigación Biomédica en Red (CIBER), the Centro de Investigación Príncipe Felipe (CIPF), and the University of the Basque Country (UPV/EHU) has developed an innovative eye [...]
28 Feb
Advancing new treatments for Retinitis Pigmentosa within NANBIOSIS
NANBIOSIS Unit 10 develops lipid-based nanoparticles for gene and drug delivery, aiming for cost-effective, non-invasive treatments for retinitis pigmentosa. Vitoria, february 2025. Retinitis pigmentosa (RP) is a congenital rare disease that leads to progressive and irreversible vision loss. Both genetic mutations and inflammation contribute significantly to the progression of the disease. Researchers from the Drug [...]
11 Sep
Gene Therapy for Cystic Fibrosis: new inspiring scientific collaboration
Researchers are advancing gene therapies for cystic fibrosis using non-viral delivery methods, focusing on patient needs and innovative treatments. Basque Country, September, 2024 – As the world comes together to mark World Cystic Fibrosis Day, from NANBIOSIS we want to highlight the collaborative efforts between our Unit 10 “Drug Formulation” (U10), the University of the [...]
09 Sep
New gene therapy for Cystic Fibrosis: an interview with Lucía Enríquez
Vasque Country, September, 2024 – In this interview, Lucía Enríquez, a PhD researcher at NANBIOSIS Unit 10, discusses her work on gene therapies for cystic fibrosis, a genetic disease that mainly affects the lungs. Her research focuses on using non-viral vectors to deliver gene-editing tools, like Prime Editing, a variation of CRISPR-Cas9, to correct mutations [...]
27 Jun
Prof. Jose Luis Pedraz, new “Académico de Número” of the Spanish Royal National Academy of Pharmacy
Madrid, June, 2024 – In a distinguished ceremony held at the Spanish Royal National Academy of Pharmacy (Real Academia Nacional de Farmacia), Professor Jose Luis Pedraz Muñoz, a prominent figure at the University of the Basque Country, was officially inducted as an “Académico de Número”. The highest position within the Royal National Academy of Pharmacy. [...]
13 Nov
Rosa Hernández of the NanoBioCel group-NANBIOSIS U10 has received the Female Talent Award 2023 Women and Science
On Thursday, November 2, the Female Talent Award, in the category of Women and Science, was awarded to Rosa Hernández from the NanoBioCel group of CIBER BBN and the U10 Drug Formulation Unit. The award is given by AMPEA (Association of Professional and Business Women of Alava). In her award speech, Rosa Hernández, highlighted that [...]
08 Nov
Impactful research with NANBIOSIS participation in the Poster Tour of CIBER-BBN & CIBEREHD Annual Conference.
2023 CIBER-BBN Annual meeting has taken place at Santemar Hotel, in Santander during November 6-7. This year the format of our annual conferences has been changed towards a collective event scheme between the CIBER-BBN and CIBEREHD thematic areas. On Monday 6 the scientific sessions werecommon for EHD and BBN, with appealing contents for the mixed [...]
15 Oct
Developing Support Technologies for adressing traslational gaps in regenerative medicine.
On the 20th of October, CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit organises the Conference “Developping support technologies for adressing traslational gaps in regenerative medicine” by Dr. James-J Yoo. The Conference will take place in the Assembly hall of the Faculty of Pharmacy on Friday 20th of October, 2023 from 12:00 to 13:00, [...]
02 Oct
3D Printing and Bioprinting for Pharmaceutical and Medical Applications
Researchers of CIBER-BBN group NanoBioCell – NANBIOSIS U10 Drug Formulation unit Jose Luis Pedraz Muñoz, Laura Saenz del Burgo Martínez, Gustavo Puras Ochoa, Jon Zarate Sesma have edited the book “3D Printing and Bioprinting for Pharmaceutical and Medical Applications” The increasing availability and decreasing costs of 3D printing and bioprinting technologies are expanding opportunities to meet medical needs. 3D [...]
22 Jun
The role of microfluidics and 3D-bioprinting in the future of exosome therapy. A high impact review
Researchers of the NanoBioCel research group of the University of the Basque Country (UPV/EHU) and CIBER BBN, belonging to NANBIOSIS U10 Drug Formulation, Bioaraba, and CONICET Foundation of Argentina, have collaborated in a studio entitled: “The role of microfluidics and 3D-bioprinting in the future of the exosome therapy” which has been published in the journal [...]

		
		
	

											

																						

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U12. Nanostructured liquid characterization unit

												

		
		
Ciber bbn


U12. Nanostructured liquid characterization unit


    

  • 

      

    • Scientific Director: Prof. Carlos Rodríguez cranqb@cid.csic.es
      • 

    • Scientific Coordinator: Jordi Esquena jemqci@iqac.csic.es
      • 

    • Entities: Colloid and Interfacial Chemistry Group (QCI) at the Institute of Advanced Chemistry of Catalonia (IQAC) & Consejo Superior de Investigaciones Científicas (CSIC)
      • 

    • Address: Jordi Girona, 18-26, 088034, Barcelona, Spain
      • 

    • Phone: +34 934 006 159
      • 

    • Web: QCI – IQAC- CSIC
      • 

    

    • 










 

IQAC
CSIC








Order request

		
		
	

		
		
U.12 – Reometro_2U.12 – Reometro_2
U.12 – tensiometro_2U.12 – tensiometro_2
U.12 – Espectrofotometro_2U.12 – Espectrofotometro_2


 








Description




Our Unit 12 is located at the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), in Barcelona and it is coordinated by the Colloidal and Interfacial Chemistry Group, led by Dr. Carlos Rodríguez. This Unit is focused on the characterization of nanostructures in liquids and liquid/liquid interfaces, such as micelles, liposomes, micro- and nano-emulsions, and nanoparticles. The unit features state-of-the-art instrumentation for the determination of various parameters such as size distribution and zeta potential (surface charge), critical micelle concentration (CMC), solubilization capacity, osmolarity, surface and interfacial tension, wettability, refractive index, turbidity, colloidal stability, density, viscosity and other rheological parameters (shear and elastic moduli, critical yield stress, etc.)






The Unit 12 has implemented and mantein the ISO9001 certification for standard quality control system.


 IQNet ISO 9001:2015 Certification 


 AENOR ISO 9001:2015 Certification 



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE 
		
U12. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017
Partner




PICCOLO-732111

Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support
European Commission-H2020
H2020-ICT-2016-1
Partner




0624_2IQBIONEURO_6_E

Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases
European Union Interreg : European Territorial Co-operation
POCTEP Interreg España-Portugal
Partner







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







CTQ2014-52687-C3-1-P
Design and applications of new biocompatible micro / nanogels obtained by advanced condensation methods (MICRONANOGELES)
MINECO
Participant




2014SGR1655
Grants for consolidated Research Groups of Catalonia
Generalitat de Catalunya
Participant




FP7-PEOPLE-2013-ITN - 606713
Biopolymer Based FOOd Delivery Systems (BIBAFOODS)
Unión Europea
Participant




Plan de Actuación 2015
Agreement of ACC1Ó with the UAB, the PRUAB, the CSIC and the CVC for the promotion of the technological transfer
Generalitat de Catalunya
Participant




TECSPR14-2-0033 
Theranostic Magnetic Nanoparticles For Cancer Diagnosis and Treatment: Magnetic Properties and Controlled Release of Anticancer Drugs (TheraMagNano)
Unión Europea
Participant




TECSPR14-2-0044
Novel antimicrobial hydrogels for contact lenses (HYDROLENSES)
Unión Europea
Participant




Acción COST CM1101
Joint Meeting of WG 3 and WG 4. Workshop "Nano-biocolloidal materials and non-equilibrium self-assembly"
Unión europea
Participant




Ref.: 308810 076/2015 
DEVELOPMENT OF INNOVATIVE FORMULATIONS FOR THE DELIVERY OF ACTIVITIES INTO THE SKIN (ES)
ALMIRALL
Participant







		

		
Publications

		

			2016


    

  • Fornaguera C., Caldero G., Solans C.. Electrolytes as a tuning parameter to control nano-emulsion and nanoparticle size. RSC Advances. 2016;6(63):58203-58211.
    • 

  • Caldero G., Montes R., Llinas M., Garcia-Celma M.J., Porras M., Solans C.. Studies on the formation of polymeric nano-emulsions obtained via low-energy emulsification and their use as templates for drug delivery nanoparticle dispersions. Colloids and Surfaces B: Biointerfaces. 2016;145:922-931.
    • 

  • Fornaguera C., Feiner-Gracia N., Caldero G., Garcia-Celma M.J., Solans C.. PLGA nanoparticles from nano-emulsion templating as imaging agents: Versatile technology to obtain nanoparticles loaded with fluorescent dyes. Colloids and Surfaces B: Biointerfaces. 2016;147:201-209.
    • 

  • Magana J.R., Kolen’Ko Y.V., Deepak F.L., Solans C., Shrestha R.G., Hill J.P. et al. From Chromonic Self-Assembly to Hollow Carbon Nanofibers: Efficient Materials in Supercapacitor and Vapor-Sensing Applications. ACS Applied Materials and Interfaces. 2016;8(45):31231-31238.
    • 

  • Perez-Carrillo L.A., Vilchez S., Mosa J., Aparicio M., Castro Y., Duran A. et al. Synthesis and properties of TiO2-P2O5 and SiO2-TiO2-P2O5 porous hybrids obtained by templating in highly concentrated emulsions. Ceramics International. 2016;42(16):18965-18973.
    • 




		

		
		
	

		
		
News U12
08 Mar
The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024
Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation. March 8th 2024, NANBIOSIS (Spain) Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper[...]
01 Mar
Women in NANBIOSIS part 5: Susana Vílchez and her insights on water-in-water emulsions and gender equality in Science
Dr. Vílchez, our esteemed colloidal chemistry researcher, discusses her focus on water-in-water emulsions and microcoacervates. She highlights gender biases in science and advocates for inclusivity and recognition of women’s contributions. This is part of a series of interviews to several female researchers within the context of International Day of Women and Girls in Science 2024 and Woman’s Day 2024. For more interviews, visit our news section here. March 2024, IQAC-CSIC, Barcelona (Spain) Dr. Susana Vílchez, an esteemed researcher in colloidal chemistry, and the technical and quality manager of Unit 12 of NANBIOSIS, offers a profound insight into her research endeavors[...]
06 Feb
‘Magic Bullets’ Against Cancer: Unveiling the Potential of DNA Nanoparticles
DNA nanoparticles to selectively target tumor tissues through precise control of the synergies between transported drugs. February 2024, IQAC-CSIC/CIBER-BBN, Barcelona. The team led by Drs. Carme Fàbrega and Ramón Eritja, in close collaboration with 3 units of the NANBIOSIS ICTS, has developed a new strategy to improve the efficacy and reduce the toxicity of anticancer drugs. They have chemically linked several cytotoxic drugs, currently used in the treatment of various types of tumors, to DNA nanostructures. These structures selectively target cancerous tissues through folate receptors. This tactic allows precise control of drug concentration and exploits their combined effect. The results[...]
25 Sep
Carlos Rodriguez-Abreu (NANBIOSIS U12) keynote speaker at the European Colloid and Interface Society ECIS 2023
Carlos Rodriguez-Abreu, Scientific Director of NANBIOSIS U12 Nanostructured liquid characterization unit  gave a Keynote presentation entitled “Chromonic liquid crystal emulsions” at the European Colloid and Interface Society ECIS 2023 conference held in Naples, Italy (September 3-8, 2023) . Chromonic liquid crystals (CLC) can be used as templates for material synthesis and, since some CLC are nontoxic and water-based, they are also interesting for biological and medical applications. The presentation included a summary of experimental results on internally structured emulsions made of CLC encapsulated in droplets, that feature various complex morphologies. Photothermal, sensing and imaging applications are envisaged.[...]
15 Nov
Happy Day of Chemistry! The  role of Chemistry in a sustainable research in health
Today, November 15 is a day of celebration for us, the Day of the Chemistry in Spain! Chemistry is the science that studies matter, how it is composed, its properties and how its structures are transformed and, as matter is everything, including living beings and ourselves, we can say that chemistry is omnipresent and transversal in all areas surrounding us. Chemistry is everywhere, we ourselves are chemistry and our health and our life is chemistry. “Everything around us is chemistry in the environment, foods, what we use and what we touch every day. Our own body is a sophisticated complex[...]
27 Jul
1st Nanomedicine Forum of CIBER-BBN/NANBIOSIS and CSIC Nanomed Conection
During the days 30 of June and 1st of July took place in Barcelona, in the auditorium of the Institute of Advanced Chemistry of Catalonia (IQAC-CSIC), the 1st Forum on Nanomedicine gathering scientists from the CSIC net Nanomed Conection and from the CIBER-BBN and its ICTS NANBIOSIS. This forum brought toguether researchers from the most eminent national research centers in nanomedicine, that during the two days meeting presented their works and findings and discussed the impact of nanomedicine in the fields of drug delivery, diagnosis and therapy. The workshop was open by the Director of IQAC-CSIC,  Jesús Joglar, the  Scientific Coordinator[...]
03 May
OPEN SUBMISSION FOR JOURNAL SPECIAL ISSUE ON OLIGONUCLEOTIDE BASED THERAPIES
Dr. Ramon Eritja, Scientific Director of NANBIOSIS unit 29 of Oligonucleotide Synthesis Platform (OSP) and Dr. Santiago Grijalvo researcher at NANBIOSIS unit 12 of Nanostructured liquid characterization, from CIBER-BBN and IQAC-CSIC, together with Dr. Andreia F. Jorge, from Coimbra Chemistry Centre (CQC), acting as guest editors of journal Pharmaceutics, of MDPI Publisher, welcome authors to submit their articles on special issues on Recent Trends in Oligonucleotide Based Therapies. In the past few decades, significant efforts have been made towards the clinical application of oligonucleotides. However, the potential of the therapeutic applications of RNA-based strategies have recently been spotlighted after the first approval of mRNA vaccines in response to COVID-19[...]
02 May
Wide representation of NANBIOSIS research in NALS 2022 and best Oral Presentation to Eloi Parladé
During the last 27-29 April, the 3rd International Conference on Nanomaterials Applied to Life Sciences 2022 (NALS 2022) has taken place in the Excellence Campus of Universidad de Cantabria in Santander (Spain), organized by the University of Cantabria and Institute Valdecilla-IDIVAL. NALS 2022 has been a multidisciplinary conference series sharing new results and ideas in the fields of biosensors, lab on a chip, drug delivery nanopharmacy. nanobiotechnology, intelligent nanomaterials, magnetic materials, nanotoxicity, antimicrobials, novel applications of 3d bioprinting and nanoimaging. NANBIOSIS has been represented at this edition by members of several of its units, among them we must highlight the set of four ora[...]

		
		
	

											

											U12-Nanostructured liquid characterization unit											

												
												•
												Read More
											

										

																			

								



						
															

									

																															
										

											

												
U13. Tissue & Scaffold Characterization Unit

												

		
		
Ciber bbn


U13. Tissue & Scaffold Characterization Unit


    

  • Scientific Director: Prof. Miguel Angel Martínez miguelam@unizar.es
    • 

  • Scientific Coordinator: Fany Peña fany@unizar.es
    • 

  • Entities: Universidad de Zaragoza. Departamento de Ingeniería Mecánica.
    • 

  • Address: Campus Río Ebro. Edificio I D I. C/ María de Luna, S/N, 50018 Zaragoza, Spain
    • 

  • Phone: 34 976 761 000 ext 5233 / 34 976 761 912
    • 

  • Web: I3A-UZ
    • 



 Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27. 
Order request

		
		
	

		
		
U13.- MicroTester INSTRON 5548U13.- MicroTester INSTRON 5548
U13.- Activation test of a rat muscleU13.- Activation test of a rat muscle
U13.- Crystalline comppresion testU13.- Crystalline comppresion test


Description


This platform is coordinated by Dr. E. Peña member of the Applied Mechanics and Bioengineering Group of the Aragón Institute of Engineering Research (I3A) at the University of Zaragoza. The objective of this unit is to provide services for structural and physical characterization of biological tissues and tissue scaffolding, including microstructure, histology and mechanical tests among others. This platform, unique in Spain as regarding its capability, has a clear and direct translational impact, especially in regenerative medicine, implant design and evaluation, as well as in the study of the mechanical behavior of living tissues (especially in the musculoskeletal and cardiovascular systems). Its relationship with the Instituto Aragonés de Ciencias de la Salud (Health Sciences Institute of Aragon), and through it with the Tissue and Blood Bank of Aragon and with the School of Veterinary Science at the Universidad de Zaragoza, allows an easy provision of tissues both from animals (mice, rabbit, sheep, pig) and humans, following in their handling the recommendations of the different ethics committees.


It has several types of INSTRON testing machines specializedin biological tissues, for the characterizationof soft tissues and fibers, as well as an X-ray microCT which allows quantitatively characterizing the microstructure of in vitro samples of hard tissues and of biomaterials for scaffolds. It also has the entire system necessary for performing high-quality histologies which would complete the structural characterization of the previously cited types of tissues (staining of preparations, immunohistochemistry in paraffin with EnVision, laser microdissection, etc.). As additional tests, equipment for determining the permeability of biological tissues and scaffolds under culture conditions, monitoring their variation over time is also available. Finally, the platform is also composed of different types of bioreactors, including perfusion or direct compression on seeded scaffolds for stimulating cell cultures for tissue engineering applications.



		
Services

		

			



FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE 
		
U13. Services & Rates

		
Equipments

		

			




		

		
		
	

		
		

		
Active projects

		

			


	






Title
Fundin: Organism
Call: Funding source 
Role







SAF2017-90810-REDI

Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II
Agencia Estatal de Investigación (AEI)
Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017
Partner




PICCOLO-732111

Multimodal highly-sensitive PhotonICs endoscope for improve in vivo COLOn Cancer diagnosis and clinical decision support
European Commission-H2020
H2020-ICT-2016-1
Partner




0624_2IQBIONEURO_6_E

Promotion of an R&I network in biological chemistry for the diagnosis and treatment of neurological diseases
European Union Interreg : European Territorial Co-operation
POCTEP Interreg España-Portugal
Partner







		

		
Other projects

		

			


	




Ref
Title
Funding Organism
Unit Role







DPI2014-54981-R 
CORNEAL TISSUE RESPONSE TO CROSS-LINKING TREATMENT. APPLICATION TO THE TREATMENT OF KERATOCONO
MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD
Participant




DPI2013-44391-PReferencia
DESIGN AND IMPROVEMENT OF DRUG-CAUSED INTRAVASCULAR DEVICES THROUGH A COMPUTATIONAL TOOL. APPLICATION TO THE DESIGN OF STENT AND BALLS IN STENOTIC INJURIES
MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD
Participant




DPI2013-44987-R
SMART_FOOT: SUPPORT SYSTEM FOR PREOPERATIVE PLANNING OF FOOT SURGERY AND INTELLIGENT DESIGN OF PERSONALIZED PLANTING PROSTHESES.
MINECO. MINISTERIO DE ECONOMIA Y COMPETITIVIDAD
Participant




DPI2016-76630-C2-1-R
IN SILICON-IN VITRO ANALYSIS TOOL OF THE APPEARANCE PROCESS AND GROWTH OF ATEROMA PLATE
MINISTERIO DE  ECONOMIA, INDUSTRIA Y COMPETITIVIDAD
Others







		

		
Publications

		

			2016


    

  • Chaure J., Serrano C., Fernandez-Parra R., Pena E., Lostale F., Gregorio M.A.D. et al. On Studying the Interaction Between Different Stent Models and Rabbit Tracheal Tissue: Numerical, Endoscopic and Histological Comparison. Annals of Biomedical Engineering. 2016;:1-14.
    • 

  • Cilla M., Perez M.M., Pena E., Martinez M.A.. Effect of Diet and Age on Arterial Stiffening Due to Atherosclerosis in ApoE−/− Mice. Annals of Biomedical Engineering. 2016;44(7):2202-2217.
    • 

  • Grasa J., Sierra M., Lauzeral N., Munoz M.J., Miana-Mena F.J., Calvo B.. Active behavior of abdominal wall muscles: Experimental results and numerical model formulation. Journal of the Mechanical Behavior of Biomedical Materials. 2016;61:444-454.
    • 

  • Ruiz-Alejos D., Pena J.A., Perez M.M., Pena E.. Experiments and Constitutive Model for Deep and Superficial Fascia. Digital Image Correlation and Finite Element Validation. Strain. 2016;52(5):436-445.
    • 

  • Calvo B., Pascual G., Pena E., Perez-Kholer B., Rodriguez M., Bellon J.M.. Biomechanical and morphological study of a new elastic mesh (Ciberlastic) to repair abdominal wall defects. Journal of the Mechanical Behavior of Biomedical Materials. 2016;59:366-378.
    • 

  • Cordero A., Hernandez-Gascon B., Pascual G., Bellon J.M., Calvo B., Pena E.. Biaxial Mechanical Evaluation of Absorbable and Nonabsorbable Synthetic Surgical Meshes Used for Hernia Repair: Physiological Loads Modify Anisotropy Response. Annals of Biomedical Engineering. 2016;:1-8.
    • 




		

		
		
	

		
		
News U13
24 Mar
Online Seminar: Microphysiological Systems for Cell Biology and Cancer Immunology
Online seminar on April 2 at 15:00h CET with Dr. Jose Maria Ayuso on microphysiological systems for cell biology and cancer immunology. Join via Zoom! Zaragoza, March 2025. The CIBER group CB06/01/0069, where our Unit 13 is located, is organizing an online seminar featuring Dr. Jose Maria Ayuso from the University of Wisconsin-Madison. The talk, titled “Microphysiological systems for cell biology and cancer immunology”, will take place on April 2, 2025, at 15:00h (CET). Dr. Ayuso’s research focuses on the development of microphysiological systems to study complex biological processes, particularly in the context of cancer immunology. His work aims to[...]
29 May
Cardiovascular disease and Computation: an innovative lecture by Prof. Shirley Jansen
Tomorrow, on the 30th of May, our Tissue & Scaffold Characterization Unit 13 organises the Conference “Understanding cardiovascular disease by means of Computation Fluid Dynamics” by Prof. Shirley Jansen. The event will take place at 12:30 in the I3A Seminar Room, Block 5, 2nd floor of the R&D Building in Campus Rio Ebro of Universidad de Zaragoza. Prof. Jansen is passionate about the importance of working alongside engineers to understand the mechanics behind many vascular pathologies such as aortic aneurysm, dissection, and peripheral arterial disease, and why close collaboration via a shared language of haemodynamics can shed light on risk[...]
08 Mar
The revolutionary path of research in NANBIOSIS and advice on Woman’s Day 2024
Our interview series delve into the journeys of 7 female researchers, their challenges, and the call for gender equality in science, inspiring the next generation. March 8th 2024, NANBIOSIS (Spain) Kicking off on 11F “International Day of Women and Girls in Science” 2024, and spanning all the way until Woman’s Day 2024, our interview series has aimed to highlight the life, career and opinions of some of the brilliant minds within our network. Today is time to wrap it up, and for this reason we present you a summary of each of them and a chance to take a deeper[...]
22 Feb
Women in NANBIOSIS part 3: Professor Fany Peña, her insights in research, parenthood, and persistence
Prof. Peña gives us her insightful point of view in overcoming challenges, embracing passion, and cultivating collaborative success towards career estabilization. February 2024, Unizar/CIBER-BBN, Zaragoza (Spain) The echo of our footsteps returns from the high ceilings filled with electrical conduits and gas pipes. An alarm sounds in the distance, while the warmth of the Zen Garden located in the center of the R&D Building reminds us once again that peace and progress will never be at odds. We continue forward across the maroon floor, towards one of the access gates that separate each wing of the building. After crossing it,[...]
10 Nov
Applications of data-driven dynamics to oncology and neuromodulation
On the 17th of November, CIBER-BBN group TME lab – NANBIOSIS U13 Tissue & Scaffold Characterization Unit. organises the Conference “Applications of data-driven dynamics to oncology and neuromodulation” by Dr. Michael Ortiz. Michael Ortiz a Frank and Ora Lee Marble Professor Emeritus of Aronautics and Mechanical Engineering at California Institute of Technology. Prior to his arrival at Caltech in 1995, he was Professor of Engineering at Brown University. Since 2020 he also holds positions as Research Chair in the Institute of Applied Mathematics, University of Bonn and as Adjunct Professor and Timoshenko Distinguished Fellow in the departments of Mechanical Engineering[...]
21 Oct
Microchannel capillarity pumping design by Prof. Guillermo Artana
On the 28th of October, we will be receiving the international visit at the  Unversity of Zaragoza from Dr. Guillermo Artana from Laboratorio de Fluidodinámica-Facultad de Ingeniería-Universidad de Buenos Aires. The title of the talk will be “Microchannel capillarity pumping design“. The invited lecture is programed within the framework of the European project “Heart On chip based on induced pluripotent Stem cell Technology for personalized Medicine (CISTEM)” and counts with European funding: Horizon 2020 – Research and Innovation Framework Programme / H2020-MSCA-RISE-2017, grant agreement No.778354 in wich the University of Zaragoza participates through CIBER-BBN group TME lab – NANBIOSIS U13[...]
05 May
Induced pluripotent stem cells in disease modelling and experimental therapies: cardiovascular perspective
On the 20th of May, we will be receiving an international visit at the  Unversity of Zaragoza from Pr. Józef Dulak from Jagiellonian University, Kraków, Poland. The title of the talk will be “Induced pluripotent stem cells in disease modelling and experimental therapies: cardiovascular perspective“. The invited lecture is programed within the framework of the European CISTEM project, in wich the University of Zaragoza participates through CIBER-BBN group TME lab – NANBIOSIS U13 Tissue & Scaffold Characterization Unit. The event will take place at 12:00 in the I3A SEMINAR (2nd floor) of Campus Rio Ebro, of University of Zaragoza Induced pluripotent[...]
22 Mar
The results of POSITION II highlighted by CORDIS: A pan-European alliance for the next generation of smart catheters
In the picture: microencapsulated cardiospheres 10X Captured Brightfield with DM_RGB_Brightfield with DM The European project POSITION-II has been selected for publication in the ‘Results in Brief’ section of the Community Research and Development Information Service (CORDIS) website. CORDIS is the European Commission’s primary source of results from the projects funded by the EU’s framework programmes for research and innovation (FP1 to Horizon 2020). The resulting short article has now been published on the CORDIS website in six languages. The European project POSITION II “A pilot line for the next generation of smart catheters and implants” is an alliance of European[...]

		
		
	

											

											U13-Tissue & Scaffold Characterization Unit											

												
												•
												Read More